| Popis: |
Aleksiewicz Tomasz, Leis Kamil, Świerczyński Wojciech, Miętkiewicz Kacper, Litwin Katarzyna, Gałązka Przemysław. Mirabegron: the review of current knowledge of safety and efficacy in the relief of overactive bladder symptoms. Journal of Education, Health and Sport. 2018;8(9):424-437. eISNN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.1403711 http://ojs.ukw.edu.pl/index.php/johs/article/view/5864 The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part b item 1223 (26/01/2017). 1223 Journal of Education, Health and Sport eissn 2391-8306 7 © The Authors 2018; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 02.08.2018. Revised: 18.08.2018. Accepted: 24.08.2018. Mirabegron: the review of current knowledge of safety and efficacy in the relief of overactive bladder symptoms Tomasz Aleksiewicz1*, Kamil Leis1, Wojciech Świerczyński1, KacperMiętkiewicz1, Katarzyna Litwin1, Przemysław Gałązka2 1 - Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 85-090 Bydgoszcz, Poland 2 - Department of General and Oncological Paediatric Surgery, Antoni Jurasz University Hospital No. 1 in Bydgoszcz, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 85-090 Bydgoszcz, Poland *- Corresponding author- Tomasz Aleksiewicz, ul. M. Curie Skłodowskiej 9 85-094 Bydgoszcz, Tel. tel. 52/585 40 15, mail - aleksiewicz.t@gmail.com abstract: Mirabegron has been registered as the first strong and selective agonist of the β3 receptor. It is currently used for relief of symptoms of overactive bladder (OAB). That onerous illness involving urgency and detrusor overactivity, that may be accompanied by incontinence, affects approx. 16% of the population. Before registration of Mirabegron, the main pharmacological and non-surgical therapeutic method was the treatment with anti-muscarinic drugs, associated with burdensome adverse effects. Clinical trials on over 10,000 participants demonstrated efficacy and safety of Mirabegron. Besides monotherapy, attempts are being made to use Mirabegron in combined therapy of OAB. The innovative mechanism of action of the drug makes it an attractive option not only in treatment of conditions of the urinary system, but also of metabolic disorders and diseases of the cardiovascular system. This article provides a review of the current knowledge and recent reports regarding Mirabegron - an alternative in treatment of the common and onerous disease of overactive bladder. key words: mirabegron, overactive bladder, review |
